Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOLENO THERAPEUTICS INCSLNO · Entity 46432 | Director | July 31, 2020 | August 03, 2020 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | June 01, 2010 | June 02, 2010 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOLENO THERAPEUTICS INC
Report date July 31, 2020 · Filed August 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,018 |
Reported balance
After 2020-07-31 transaction · row 1
1 source rowRow 1 · 2020-07-31 · Grant · Acquired 1,018 · Balance 1,018 F1: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on July 31, 2020. The RSUs are for the benefit of, and ultimately will be transferred to, Forward Ventures V, L.P. of which the Reporting Person serves as a managing member. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on July 31, 2020. The RSUs are for the benefit of, and ultimately will be transferred to, Forward Ventures V, L.P. of which the Reporting Person serves as a managing member.
VERTEX PHARMACEUTICALS INC / MA
Report date June 01, 2010 · Filed June 02, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.24 · Expires 2020-05-31 | Direct | 20,000 |
Reported balance
After 2010-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2010-06-01 · Grant · Acquired 20,000 · Balance 20,000 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2020 Filed Aug 3, 2020 21:35 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 1,018 | $1.72 | $1,750.96 |
DisclosureSEC source: 0000899243-20-021009 · doc4.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on July 31, 2020. The RSUs are for the benefit of, and ultimately will be transferred to, Forward Ventures V, L.P. of which the Reporting Person serves as a managing member. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:44 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,553 | $3.05 | $10,836.65 |
DisclosureSEC source: 0000899243-20-011972 · doc4.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,553 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on April 30, 2020. The RSUs are for the benefit of, and ultimately will be transferred to, Forward Ventures V, L.P. of which the Reporting Person serves as a managing member. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:16 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 6,866 | $3.35 | $23,001.10 |
DisclosureSEC source: 0000899243-20-001972 · doc4.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,866 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on January 22, 2020. The RSUs are for the benefit of, and ultimately will be transferred to, Forward Ventures V, L.P. of which the Reporting Person serves as a managing member. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:42 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000899243-19-016673 · doc4.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is June 10, 2019) or the day before the 2019 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| June 11, 2018 Filed Jun 18, 2018 22:16 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 15,931 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000899243-18-017055 · doc4.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,931 Underlying: Common Stock · 15,931 shares Expires 2028-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is June 11, 2018) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| February 05, 2018 Filed Feb 8, 2018 00:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,813 | $1.73 | $6,582.38 |
DisclosureSEC source: 0000899243-18-003155 · doc4.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,459,361 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018, or $1.7263. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 21:58 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 12,661 | $0.52 | $6,583.72 |
DisclosureSEC source: 0000899243-17-023570 · doc4.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,018 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on September 29, 2017, or $0.52. Read SEC document |
| July 06, 2017 Filed Jul 18, 2017 00:57 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 10,793 | $0.61 | $6,583.73 |
DisclosureSEC source: 0000899243-17-018367 · doc4.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,357 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on July 6, 2017, or $0.61. Read SEC document |
| May 08, 2017 Filed May 9, 2017 20:34 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 45,139 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000899243-17-012480 · doc4.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,139 Underlying: Common Stock · 45,139 shares Expires 2027-05-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is May 8, 2017) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| April 07, 2017 Filed Apr 14, 2017 01:31 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantCommon Stock | 2,564 | $0.63 | $1,615.32 |
DisclosureSEC source: 0000899243-17-010285 · doc4.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,564 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on April 7, 2017, or $0.63. Read SEC document |
| March 07, 2017 Filed Mar 21, 2017 18:29 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0000899243-17-008284 · doc4.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of the Vesting Commencement Date (which is March 7, 2017), and shall continue to vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Participant continuing to be a Service Provider (as defined in the Plan) through each such date. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000031 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 18:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $29.89 | $0.00 |
DisclosureSEC source: 0000875320-09-000043 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2019-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2008 Filed Jun 2, 2008 20:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $28.40 | $0.00 |
DisclosureSEC source: 0000875320-08-000039 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2018-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2007 Filed Jun 4, 2007 16:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000064 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2017-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| December 14, 2006 Filed Dec 15, 2006 16:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 420 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0000875320-06-000119 · edgar.xml · derivative · entry 5 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,104 Underlying: Common Stock · 420 shares Expires 2009-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Right to buy under the 1996 Stock and Option Plan, fully vested as of 4/29/1999. Read SEC document |
| December 14, 2006 Filed Dec 15, 2006 16:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 49,599 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0000875320-06-000119 · edgar.xml · derivative · entry 4 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,524 Underlying: Common Stock · 49,599 shares Expires 2009-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under the 1996 Stock and Option Plan, fully vested as of 12/7/1999. Read SEC document |
| December 14, 2006 Filed Dec 15, 2006 16:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 50,019 | $37.81 | $1,891,218.39 |
DisclosureSEC source: 0000875320-06-000119 · edgar.xml · nonDerivative · entry 3 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 F1 · kind: Transaction made pursuant to Dr. Collinson's company approved trading plan established under Rule 10b5-1. Read SEC document |
| December 14, 2006 Filed Dec 15, 2006 16:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 420 | $9.68 | $4,065.60 |
DisclosureSEC source: 0000875320-06-000119 · edgar.xml · nonDerivative · entry 2 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2006 Filed Dec 15, 2006 16:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 49,599 | $18.25 | $905,181.75 |
DisclosureSEC source: 0000875320-06-000119 · edgar.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2006 Filed Aug 3, 2006 17:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0000875320-06-000073 · edgar.xml · derivative · entry 3 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,123 Underlying: Common Stock · 30,000 shares Expires 2009-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under the 1996 Stock and Option Plan, fully vested as of 1/18/2002. Read SEC document |
| August 02, 2006 Filed Aug 3, 2006 17:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,000 | $32.62 | $978,600.00 |
DisclosureSEC source: 0000875320-06-000073 · edgar.xml · nonDerivative · entry 2 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 F1 · kind: Transaction made pursuant to Dr. Collinson's company approved trading plan established under Rule 10b5-1. Read SEC document |
| August 02, 2006 Filed Aug 3, 2006 17:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,000 | $9.68 | $290,400.00 |
DisclosureSEC source: 0000875320-06-000073 · edgar.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2006 Filed Jul 5, 2006 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0000875320-06-000059 · edgar.xml · derivative · entry 3 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,123 Underlying: Common Stock · 30,000 shares Expires 2009-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under the 1996 Stock and Option Plan, fully vested as of 1/18/2002. Read SEC document |
| July 03, 2006 Filed Jul 5, 2006 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,000 | $35.84 | $1,075,200.00 |
DisclosureSEC source: 0000875320-06-000059 · edgar.xml · nonDerivative · entry 2 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 F1 · kind: Transaction made pursuant to Dr. Collinson's company approved trading plan established under Rule 10b5-1. Read SEC document |
| July 03, 2006 Filed Jul 5, 2006 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,000 | $9.68 | $290,400.00 |
DisclosureSEC source: 0000875320-06-000059 · edgar.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2006 Filed Jun 5, 2006 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0000875320-06-000056 · edgar.xml · derivative · entry 3 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,123 Underlying: Common Stock · 30,000 shares Expires 2009-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under the 1996 Stock and Option Plan, fully vested as of 1/18/2002. Read SEC document |
| June 02, 2006 Filed Jun 5, 2006 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,000 | $34.76 | $1,042,800.00 |
DisclosureSEC source: 0000875320-06-000056 · edgar.xml · nonDerivative · entry 2 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 F1 · kind: Transaction made pursuant to Dr. Collinson's company approved trading plan established under Rule 10b5-1. Read SEC document |
| June 02, 2006 Filed Jun 5, 2006 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,000 | $9.68 | $290,400.00 |
DisclosureSEC source: 0000875320-06-000056 · edgar.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2006 Filed Jun 2, 2006 17:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0000875320-06-000054 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,123 Underlying: Common Stock · 20,000 shares Expires 2016-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| May 02, 2006 Filed May 3, 2006 16:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0000875320-06-000041 · edgar.xml · derivative · entry 3 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,123 Underlying: Common Stock · 30,000 shares Expires 2009-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under Aurora Bioscience Corporation 1996 Stock and Option Plan, fully vested as of 1/18/2002. Read SEC document |
| May 02, 2006 Filed May 3, 2006 16:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,000 | $34.81 | $1,044,300.00 |
DisclosureSEC source: 0000875320-06-000041 · edgar.xml · nonDerivative · entry 2 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 F1 · kind: Transaction made pursuant to Dr. Collinson's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 02, 2006 Filed May 3, 2006 16:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,000 | $9.68 | $290,400.00 |
DisclosureSEC source: 0000875320-06-000041 · edgar.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2006 Filed Apr 4, 2006 19:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0000875320-06-000035 · edgar.xml · derivative · entry 3 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,123 Underlying: Common Stock · 30,000 shares Expires 2009-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under Aurora Bioscience Corporation 1996 Stock and Option Plan, fully vested as of 1/18/2002. Read SEC document |
| April 03, 2006 Filed Apr 4, 2006 19:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,000 | $36.11 | $1,083,300.00 |
DisclosureSEC source: 0000875320-06-000035 · edgar.xml · nonDerivative · entry 2 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 F1 · kind: Transaction made pursuant to Dr. Collinson's company approved trading plan established under Rule 10b5-1. Read SEC document |
| April 03, 2006 Filed Apr 4, 2006 19:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,000 | $9.68 | $290,400.00 |
DisclosureSEC source: 0000875320-06-000035 · edgar.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2006 Filed Mar 6, 2006 16:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0000875320-06-000024 · edgar.xml · derivative · entry 3 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,123 Underlying: Common Stock · 30,000 shares Expires 2009-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under Aurora Bioscience Corporation 1996 Stock and Option Plan, fully vested as of 1/18/2002. Read SEC document |
| March 02, 2006 Filed Mar 6, 2006 16:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,000 | $43.64 | $1,309,200.00 |
DisclosureSEC source: 0000875320-06-000024 · edgar.xml · nonDerivative · entry 2 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 F1 · kind: Transaction made pursuant to Dr. Collinson's company approved trading plan established under Rule 10b5-1. Read SEC document |
| March 02, 2006 Filed Mar 6, 2006 16:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,000 | $9.68 | $290,400.00 |
DisclosureSEC source: 0000875320-06-000024 · edgar.xml · nonDerivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2005 Filed Jun 3, 2005 14:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0000875320-05-000025 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,123 Underlying: Common Stock · 10,000 shares Expires 2015-05-31 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2004 Filed Jun 2, 2004 15:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000875320-04-000067 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,123 Underlying: Common Stock · 7,500 shares Expires 2014-05-31 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2003 Filed Jun 3, 2003 19:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $14.46 | $0.00 |
DisclosureSEC source: 0000875320-03-000014 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,623 Underlying: Common Stock · 7,500 shares Expires 2013-05-31 F1 · derivative.exercise_date: Right to buy under the 1996 Stock and Option Plan. Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.